Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients

NCT04717011

SARS-CoV-2

UNKNOWN

Impact of the Coronavirus Disease 2019 (COVID-19) on Sperm Parameters

NCT04937608

Covid19 Infertility, Male

TERMINATED

Impact of Cryopreservation Methods on Post-Thaw SARS-CoV-2 in Semen Samples

NCT06703723

COVID 19

COMPLETED

Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy.

NCT06384794

Infertility, Male Sperm Count, Low

RECRUITING NA

Human Sperm Markers of Cryodamage Resistance

NCT02535377

Fertility

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time.

Knowledge of the possible presence, infectivity and persistence of ZIKV in semen will provide evidence-based data for

1. estimating of the risk of sexual transmission of ZIKV in the general population
2. antenatal guidelines for the prevention of sexual transmission of ZIKV to the fetus
3. advising couples on the length of time that pregnancy should be avoided in women wishing to conceive after their partner's ZIKV infection
4. strategies to prevent transmission of ZIKV infection through assisted reproductive treatment (ART)
5. advice on gamete cryopreservation
6. optimising investigations for diagnosis of ZIKV in males.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Zika Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Semen analysis and semen PCR for Zika virus

Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male aged 18-50 years
* ZIKV symptoms within the preceding thirty days
* Confirmed ZIKV infection (WHO criteria)
* Able to ejaculate to produce a semen sample